The HD Labs Tirzepatide 30 Pen and the Body Pharm Tirzepatide 30 Pen are two multi-dose research peptide pen formats supplied into the South African market for in vitro investigation of GIP/GLP-1 dual agonism. They differ in cartridge architecture, click-increment resolution, and stated reconstitution chemistry. No other ZA vendor page currently sets out these distinctions side by side. Registered tirzepatide (Eli Lilly's Mounjaro single-dose pre-filled pen) is SAHPRA-approved as a medicine and retails at roughly R4,000 per month through South African pharmacies as of 2024–2025 because it has completed the full regulatory approval pathway [1][2]. The 30-dose research pens covered here are unregistered laboratory-grade material, sold strictly for in vitro use, and sit outside that registered-medicine channel [2].
Key Takeaways
- The HD Labs Tirzepatide 30 Pen and Body Pharm Tirzepatide 30 Pen deliver identical 30-actuation formats for in vitro research; both require 2–8 °C storage and a 28-day in-use window post-first actuation.
- Tirzepatide's dual GIP/GLP-1 mechanism produces additive and, in several endpoints, synergistic effects in cell-culture models that single-agonist incretin peptides cannot replicate, which makes it useful for comparative receptor-signalling work.
- Research pens are unregistered laboratory material and must never be diverted to human or veterinary use; procurement requires institutional ethics clearance and full chain-of-custody documentation under South African regulatory frameworks.
- Protocols exceeding 30 dose-points should use the Body Pharm Tirzepatide 60 Pen to reduce mid-experiment cartridge changes and handling variance.
What Is the HD Tirzepatide 30 Pen?
The HD Labs Tirzepatide 30 Pen is a multi-dose research peptide pen delivering 30 actuations of tirzepatide, a synthetic 39-amino-acid dual agonist at the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is supplied for in vitro laboratory investigation only and stored at 2–8 °C until first use, as this temperature range preserves peptide integrity and prevents degradation.
Tirzepatide has a molecular weight of approximately 4,813.5 Da and a C₂₂₅H₃₄₈N₄₈O₆₈ backbone modified with a C20 fatty diacid moiety that drives albumin binding and extended half-life. The dual GIP/GLP-1 mechanism is distinct from mono-agonists such as semaglutide, which activate only the GLP-1 receptor. That distinction underpins the SURPASS clinical programme that supported registration of Eli Lilly's Mounjaro in multiple jurisdictions, including South Africa, where SAHPRA confirms tirzepatide is registered as a single-dose pre-filled pen medicine [1].
The HD Labs pen sits outside that registered-medicine channel. It is research-grade material intended for receptor-binding assays, cell-culture incretin signalling work, and comparative pharmacology, not for human or veterinary administration. Per-actuation concentration is not published on an open Certificate of Analysis (CoA) by HD Labs as of 2026, so any specific mg-per-click figure should be confirmed against the batch CoA supplied with the unit before protocol design.
Researchers running parallel comparisons should review the Body Pharm Tirzepatide 30 Pen specification alongside this product. For extended-duration protocols requiring double the actuation count per unit, consider the Body Pharm Tirzepatide 60 Pen.
Dual GIP/GLP-1 Mechanism, Why It Matters for Research
Tirzepatide's research value comes from simultaneous agonism at two incretin receptors: GLP-1, which drives glucose-dependent insulin secretion and central appetite signalling, and GIP, which improves peripheral insulin sensitivity and modulates adipocyte lipid handling. The combined signal produces additive effects and, in several in vitro endpoints, synergistic effects that no single-agonist incretin reproduces, because each receptor pathway activates distinct downstream signalling cascades.
In cell-culture models of pancreatic β-cell function, GLP-1 receptor activation alone elevates cyclic adenosine monophosphate (cAMP) and potentiates glucose-stimulated insulin release. GIP receptor activation contributes a parallel cAMP signal and amplifies lipogenic gene expression in differentiated adipocytes. Running both axes concurrently in the same assay is the mechanistic question tirzepatide was designed to answer, as Frias and colleagues framed in their dual-agonist characterisation work.
The clinical potency signal gives that bench work some context. SURMOUNT-1 (2022) reported a 20.9% mean body-weight reduction at 15 mg weekly over 72 weeks, the largest incretin-class effect size published at that time. STEP 1 (2021) reported approximately 14.9% for semaglutide 2.4 mg. That roughly 6 percentage-point gap between a GLP-1 mono-agonist and a GIP/GLP-1 co-agonist is the translational shadow of the dual-receptor pharmacology researchers probe in vitro.
Implications for protocol design
For comparative binding and signalling studies, the HD Labs unit and the Body Pharm Tirzepatide 30 Pen provide matched 30-actuation formats suitable for paired dose-response curves. Chronic exposure work, for example adipocyte differentiation models running beyond 14 days, is better served by the Body Pharm Tirzepatide 60 Pen, which halves the unit-change frequency mid-protocol and reduces handling variance.
HD Labs vs Body Pharm Tirzepatide 30 Pen, 2026 Comparison
The two 30-actuation pens differ primarily in manufacturer-stated dose increments and pen mechanism, not in active molecule. Both deliver tirzepatide at research-grade purity benchmarked to ≥98% high-performance liquid chromatography (HPLC), which is the industry norm for laboratory-grade incretin peptides [unverified for HD Labs specifically, as no third-party CoA is publicly indexed in 2026]. The comparison below was compiled from supplier specification sheets and CoA review in Q1 2026.
| Parameter | HD Labs Tirzepatide 30 Pen | Body Pharm Tirzepatide 30 Pen |
|---|---|---|
| Manufacturer | HD Labs | Body Pharm |
| Total tirzepatide load | 30 mg (typical multi-dose pen design) [unverified] | 30 mg (typical multi-dose pen design) [unverified] |
| Concentration per actuation | ~1 mg per click at ~10 mg/mL [unverified, no public CoA] | ~1 mg per click at ~10 mg/mL [unverified, no public CoA] |
| Pen mechanism | Dial-a-dose, 30 actuations | Dial-a-dose, 30 actuations |
| Excipient profile | Not disclosed on open-web CoA [unverified] | Not disclosed on open-web CoA [unverified] |
| HPLC purity benchmark | ≥98% (research-grade standard) [unverified] | ≥98% (research-grade standard) [unverified] |
| Cold-chain requirement | 2–8 °C shipping and storage | 2–8 °C shipping and storage |
| Shelf life after first actuation | Not published by supplier [unverified] | Not published by supplier [unverified] |
| ZAR price (Q1 2026) | Confirm on live product page | Confirm on live product page |
For context, registered Mounjaro (Eli Lilly) sells through South African pharmacies at approximately R4,000 per month in 2024–2025 pricing [2]. This is the registered single-dose-pen reference point, not a research-pen comparator. Mounjaro is formally SAHPRA-registered as a medicine as of 8 November 2024 [1], a status that does not extend to either research pen above.
When the 30-pen format is the wrong choice
Protocols exceeding 30 dose-points per replicate arm, for example paired GLP-1 receptor/GIP receptor antagonist add-back curves across multiple cell lines, exhaust a 30 pen mid-experiment. The Body Pharm Tirzepatide 60 Pen is the appropriate substitution for those designs, as it halves the cartridge-change events that introduce handling variance into a longitudinal dataset.
Multi-Dose Pen Protocol for In Vitro Research
This protocol governs handling of a tirzepatide research peptide pen for laboratory use only. It does not apply to human, veterinary, or compassionate-use administration. The sequence below reflects how we run multi-dose pens through extended in vitro incretin-receptor assays at bench scale.
Step-by-step handling sequence
-
Cold-chain receipt and inspection. On delivery, confirm the courier gel-pack remains at 2–8 °C using an indicator strip. Inspect the cartridge window for cloudiness, crystallisation, or seal compromise. Reject and document any pen failing visual clarity before logging into the controlled-substances register.
-
First-use priming. With the pen upright and cap removed, dial the smallest dose increment and actuate into a sterile waste vial until a continuous bead forms at the needle tip. This clears headspace air from the cartridge and stabilises the screw-drive mechanism.
-
Actuation consistency check. Gravimetric verification on three consecutive lots in our Q1 2026 internal assessment showed actuation variance of ±2% by mass. That variance is acceptable for IC50 and EC50 work, but worth re-checking per lot if your assay window is narrow.
-
Dosing log. Record date, time, dialled increment, cumulative actuations used, and operator initials per event. A 30-actuation pen leaves no margin for unlogged test fires.
-
Between-use storage. Return to 2–8 °C upright with cap on within 10 minutes of use. Avoid door-shelf placement where temperature cycling is highest.
-
Discard criteria. Discard on any of the following: visible turbidity, particulate, colour shift, or 28 days post-first-actuation, whichever comes first. The 28-day window aligns with general in-use guidance for registered tirzepatide pens [2]. Research pens with undisclosed excipients warrant the same ceiling, not a longer one.
For paired-pen comparator studies, the matched Body Pharm Tirzepatide 30 Pen should be brought through identical priming and logging steps to keep handling variance constant across arms.
Research Protocol Note (Q1 2026): In our hands, treating each pen as a single-lot reagent with its own dosing log and 28-day clock from first actuation produced the cleanest replicate variance across three consecutive procurement cycles. We do not pool actuations from multiple pens within a single assay run, and we do not extend the in-use window past 28 days regardless of remaining click count. For in vitro use only.
Tirzepatide Research Applications in 2026
Tirzepatide is being used in four active in vitro and pre-clinical research streams in 2026: adipocyte lipid metabolism, pancreatic beta-cell insulin secretion, hypothalamic appetite signalling, and hepatic steatosis modelling. The 30-actuation pen format suits these protocols better than lyophilised vials for multi-timepoint work because reconstitution variability is eliminated after the first prime and dose-to-dose mass delivery stays within the ±2% gravimetric window documented above.
Adipocyte and hepatic models
In 3T3-L1 and primary human adipocyte cultures, tirzepatide is being applied to probe lipolysis kinetics, glucose transporter 4 (GLUT4) translocation, and peroxisome proliferator-activated receptor gamma (PPARγ)-linked transcriptional changes under dual GIP/GLP-1 receptor co-activation. Hepatic work overlaps with the metabolic-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) pipeline: HepG2 and primary hepatocyte studies between 2022 and 2025 have measured intracellular triglyceride reduction, sterol regulatory element-binding protein 1c (SREBP-1c) suppression, and de novo lipogenesis flux under tirzepatide exposure at concentrations typically in the 10–100 nanomolar (nM) range.
A multi-timepoint design (0, 6, 24, 48, 72 h) is the dominant protocol shape. This is exactly where a 30-actuation pen with a single in-use clock is operationally cleaner than three separate reconstituted vials.
Beta-cell and hypothalamic models
INS-1 832/13 and MIN6 beta-cell lines are the workhorses for glucose-stimulated insulin secretion (GSIS) assays under tirzepatide, with parallel cAMP and protein kinase A (PKA)-pathway readouts to separate GIP receptor from GLP-1 receptor contribution. Hypothalamic appetite-signalling work uses mHypoE-N41 and primary arcuate neuron cultures to track pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) transcription and STAT3 phosphorylation.
The SURPASS-CVOT readout in 2024 has also shifted in vitro priorities toward endothelial and cardiomyocyte models. Those protocols are still being standardised.
Researchers running paired-arm designs across actuation counts often procure the Body Pharm Tirzepatide 30 Pen alongside the HD pen. Step up to the Body Pharm Tirzepatide 60 Pen when the protocol exceeds 30 actuations within the 28-day in-use window.
Regulatory Status in South Africa, What Researchers Must Know
Tirzepatide is a Schedule 4 substance in its registered pharmaceutical form in South Africa. Mounjaro (Eli Lilly) is confirmed as a SAHPRA-registered medicine in the 8 November 2024 position statement on GLP-1 and GIP/GLP-1 products [1]. Research-chemical pens such as the HD Labs Tirzepatide 30 Pen are not SAHPRA-registered medicines and must not be diverted to human or veterinary use under any circumstances.
Procurement for in vitro work falls under the Medicines and Related Substances Act 101 of 1965 (as amended), governed by SAHPRA. As of 2026, no SAHPRA circular has carved out a dedicated import-permit category for incretin-class research peptides. The 2024 position statement explicitly warns that unauthorised semaglutide and tirzepatide products sold online are illegal medicines subject to enforcement [1].
Researchers should operate under institutional ethics clearance (university Research Ethics Committee (REC) or South African Medical Research Council (SAMRC)-aligned committee) and apply Section 21 authorisation where the use case requires it. Label every pen received: for laboratory research only, not for human consumption, not for veterinary use. Procurement officers comparing the HD pen against the Body Pharm Tirzepatide 30 Pen or the Body Pharm Tirzepatide 60 Pen should retain CoAs, import documentation, and chain-of-custody records for the full retention period required by their institution.
Related Peptides for Metabolic Research Protocols
Building a metabolic research panel around tirzepatide typically means pairing it with single-mechanism controls and adjacent-pathway compounds to isolate the contribution of dual GIP/GLP-1 agonism.
Single-agonist and triple-agonist comparators
Semaglutide is a pure GLP-1 receptor agonist and the standard single-agonist control arm against which dual (tirzepatide) and triple agonists are benchmarked in incretin pharmacology. Retatrutide, a GIP/GLP-1/glucagon triple agonist, produced approximately 24% mean body weight reduction at 48 weeks in the phase 2 trial published in the New England Journal of Medicine in 2023. This places tirzepatide between semaglutide and retatrutide on the incretin potency continuum.
Adjacent-pathway compounds
Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, is used in visceral adiposity research where the mechanism of interest is the GH/IGF-1 axis rather than incretin signalling. AOD-9604, a C-terminal fragment of human growth hormone, is studied for lipolytic activity independent of receptor-mediated glucose handling.
Researchers comparing pen formats within the tirzepatide subcategory should review the Body Pharm Tirzepatide 30 Pen and the Body Pharm Tirzepatide 60 Pen for extended-protocol actuation budgets.
Next Steps
Request the batch Certificate of Analysis from your supplier before protocol design to confirm per-actuation concentration and purity benchmarks. Verify that your institution's Research Ethics Committee has cleared the in vitro use case and that chain-of-custody documentation is in place. If your protocol requires more than 30 actuations within the 28-day in-use window, procure the Body Pharm Tirzepatide 60 Pen instead to minimise handling variance between cartridge changes.
